A 74-yr-old man with prostatic adenocarcinoma underwent magnetic resonance 1H-spectroscopic imaging (1H-MRSI) of the prostate. Based on the results, he was treated with combination therapy using complete androgen blockade (leuprorelin acetate 3.75 mg every 4 wk plus bicalutamide 50 mg daily) and a somatostatin analogue (lanreotide acetate 60 mg every 4 wk). Serum prostate-specific antigen and chromogranin A levels steadily decreased over a 12-mo follow-up period, at which time the patient is alive without disease progression and with a complete objective and symptomatic response. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: Magnetic resonance imaging with 1H-spectroscopy / Sciarra, Alessandro; Valeria, Panebianco; Ciccariello, Mauro; Salciccia, Stefano; Gentilucci, Alessandro; Danilo, Lisi; Passariello, Roberto; Gentile, Vincenzo; DI SILVERIO, Franco. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 53:3(2008), pp. 652-655. [10.1016/j.eururo.2007.02.010]
Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: Magnetic resonance imaging with 1H-spectroscopy
SCIARRA, Alessandro;Valeria Panebianco;CICCARIELLO, Mauro;SALCICCIA, STEFANO;GENTILUCCI, ALESSANDRO;PASSARIELLO, Roberto;GENTILE, Vincenzo;DI SILVERIO, Franco
2008
Abstract
A 74-yr-old man with prostatic adenocarcinoma underwent magnetic resonance 1H-spectroscopic imaging (1H-MRSI) of the prostate. Based on the results, he was treated with combination therapy using complete androgen blockade (leuprorelin acetate 3.75 mg every 4 wk plus bicalutamide 50 mg daily) and a somatostatin analogue (lanreotide acetate 60 mg every 4 wk). Serum prostate-specific antigen and chromogranin A levels steadily decreased over a 12-mo follow-up period, at which time the patient is alive without disease progression and with a complete objective and symptomatic response. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
